Sustained-release XXXX intravitreal implant for persistent @entity1103 after vitrectomy for epiretinal membrane.

@entity1 @entity9170 @entity1103 @entity6654 @entity619
BACKGROUND AND OBJECTIVE: Persistent @entity1103 ( @entity1103 ) after surgical @entity6654 (ERM) may impair postoperative visual recovery. Sustained-release @entity619 intravitreal implant ( @entity9170 ) was used to treat recalcitrant @entity1103 after vitrectomy for ERM. @entity1 AND METHODS: Retrospective chart review of eyes treated with @entity9170 for @entity1103 after ERM removal. Visual and anatomic outcomes were evaluated. RESULTS: Five eyes with refractory @entity1103 on optical coherence tomography (OCT) after ERM surgery were treated with @entity9170 . Four of five eyes demonstrated reduction in macular thickness on OCT (mean: 106  m), with mean percentage reduction in central foveal thickness of 25%. Visual acuity improved by one or more Snellen lines in four of five eyes. @entity9170 effect duration was 3 to 9 months. Two eyes with OCT and visual improvement after initial @entity9170 received multiple @entity9170 implants for maintenance therapy. CONCLUSION: Inflammatory factors may contribute to persistent @entity1103 after vitrectomy for ERM. @entity9170 may be a treatment option in such cases.
